Clene Inc. (CLNN) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 14.17
30Y Low2.3·High148.9
ROE
↓
N/A
—
5yr avg: -715.6%
30Y Low-378%·High-6%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low9.3·High9.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CLNN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Clene Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $74M | $58M | $37M | $31M | $65M | $252M | $631M | $728M | $618M |
| Enterprise Value | $90M | $74M | $46M | $34M | $79M | $226M | $576M | $722M | $620M |
| P/E Ratio → | -2.79 | — | — | — | — | — | — | — | — |
| P/S Ratio | 369.50 | 289.36 | 107.97 | 47.58 | 137.85 | 349.09 | 3062.35 | — | — |
| P/B Ratio | — | — | — | 2.32 | 20.14 | 20.04 | 1849.99 | 148.89 | 123.56 |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CLNN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 371.78 | 133.38 | 52.68 | 166.38 | 312.79 | 2795.59 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | 1782.05 |
| EV / EBIT | — | — | — | — | — | — | — | — | 31924.40 |
| EV / FCF | — | — | — | — | — | — | — | — | — |
CLNN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Clene Inc. earns an operating margin of -11541.5%. Operating margins have compressed from -6198.8% to -11541.5% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.5% | 78.5% | 79.5% | 81.5% | 94.5% | 60.0% | 68.4% | — | — |
| Operating Margin | -11541.5% | -11541.5% | -9676.3% | -6198.8% | -10234.5% | -6912.6% | -9812.6% | — | — |
| Net Profit Margin | -13086.5% | -13086.5% | -11520.5% | -7569.4% | -6325.2% | -1347.2% | -9357.8% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -1738.4% | -595.5% | -377.9% | -150.6% | -737.5% | -326.8% | -5.5% |
| ROA | -115.1% | -115.1% | -98.9% | -102.2% | -55.6% | -14.8% | -46.4% | -52.1% | -0.6% |
| ROIC | — | — | -299.7% | -181.7% | -2357.6% | — | — | -379.3% | — |
| ROCE | -189.2% | -189.2% | -150.2% | -140.6% | -110.4% | -88.0% | -60.2% | -56.8% | -0.7% |
CLNN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $16M ($22M total debt minus $5M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 2.40 | 9.83 | 1.91 | 12.68 | 0.59 | 0.64 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | 9.26 |
| Net Debt / Equity | — | — | — | 0.25 | 4.17 | -2.08 | -161.15 | -1.21 | 0.50 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | 7.13 |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -8.61 | -8.61 | -8.69 | -9.86 | -8.08 | -10.69 | -18.86 | -182.58 | — |
CLNN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.83x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 1.53x to 0.83x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.83 | 0.83 | 1.57 | 1.53 | 2.11 | 9.06 | 5.40 | 2.20 | 3.56 |
| Quick Ratio | 0.83 | 0.83 | 1.56 | 1.53 | 2.10 | 9.05 | 5.38 | 2.19 | 3.56 |
| Cash Ratio | 0.48 | 0.48 | 1.18 | 1.38 | 1.68 | 8.35 | 5.08 | 2.04 | 3.35 |
| Asset Turnover | — | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | — | — |
| Inventory Turnover | 1.16 | 1.16 | 1.03 | 3.27 | 0.60 | 7.05 | 0.34 | 32.14 | — |
| Days Sales Outstanding | — | — | 417.30 | 746.74 | 2288.77 | 814.31 | 3843.13 | — | — |
CLNN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Clene Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $10M | $7M | $5M | $3M | $3M | $4M | $3M | $3M |
Peer Comparison
Compare CLNN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CLNNYou | $74M | -2.8 | — | — | 78.5% | -11541.5% | — | — | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 SAVA | $94M | -3.8 | — | — | — | — | -17.2% | -634.1% | — |
 ACIU | $298M | -3.3 | — | — | 100.0% | -1927.3% | -89.6% | -99.2% | — |
 NRXP | $85M | -2.3 | — | — | — | -1324.4% | — | — | — |
 BIIB | $28B | 21.7 | 11.4 | 13.8 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 ARVN | $652M | -8.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 AVXL | $289M | -5.8 | — | — | — | — | -43.1% | — | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See CLNN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CLNN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CLNN vs ACAD
Side-by-side business, growth, and profitability comparison vs ACADIA Pharmaceuticals Inc..
Start ComparisonCLNN — Frequently Asked Questions
Quick answers to the most common questions about buying CLNN stock.
What is Clene Inc.'s P/E ratio?
Clene Inc.'s current P/E ratio is -2.8x. This places it at the 50th percentile of its historical range.
Is CLNN stock overvalued?
Based on historical data, Clene Inc. is trading at a P/E of -2.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Clene Inc.'s profit margins?
Clene Inc. has 78.5% gross margin and -11541.5% operating margin.